

Lorraine Harper

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7824242/publications.pdf>

Version: 2024-02-01

82
papers

6,782
citations

117571

34
h-index

79644

73
g-index

83
all docs

83
docs citations

83
times ranked

4165
citing authors

#	ARTICLE	IF	CITATIONS
1	Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Annals of Internal Medicine</i> , 2009, 150, 670.	2.0	790
2	Long-term patient survival in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 488-494.	0.5	719
3	Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 2381.	3.8	524
4	Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2020, 382, 622-631.	13.9	465
5	Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2756-2767.	3.0	448
6	Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 955-960.	0.5	348
7	Prospective Study of TNF Blockade with Infliximab in Anti-Neutrophil Cytoplasmic Antibody-Associated Systemic Vasculitis. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 717-721.	3.0	345
8	Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1036-1043.	0.5	344
9	BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. <i>Rheumatology</i> , 2014, 53, 2306-2309.	0.9	246
10	Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 177-184.	0.5	214
11	Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 399-405.	0.5	165
12	Neutrophil priming and apoptosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis. <i>Kidney International</i> , 2001, 59, 1729-1738.	2.6	148
13	A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. <i>Arthritis Care and Research</i> , 2011, 63, 588-596.	1.5	147
14	Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: A matched-pair cohort study. <i>Arthritis and Rheumatism</i> , 2009, 60, 3493-3500.	6.7	110
15	Anti-Neutrophil Cytoplasm-Associated Glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1224-1234.	3.0	105
16	Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. <i>Rheumatology</i> , 2015, 54, 471-481.	0.9	104
17	Antineutrophil Cytoplasmic Antibodies Induce Reactive Oxygen-Dependent Dysregulation of Primed Neutrophil Apoptosis and Clearance by Macrophages. <i>American Journal of Pathology</i> , 2000, 157, 211-220.	1.9	101
18	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1243-1249.	0.5	93

#	ARTICLE	IF	CITATIONS
19	The characterisation and determinants of quality of life in ANCA associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 207-211.	0.5	74
20	Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients. <i>Lancet</i> , The, 2021, 398, 1038-1041.	6.3	73
21	Dendritic cell uptake of human apoptotic and necrotic neutrophils inhibits CD40, CD80, and CD86 expression and reduces allogeneic T cell responses: Relevance to systemic vasculitis. <i>Arthritis and Rheumatism</i> , 2003, 48, 2362-2374.	6.7	71
22	New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis. <i>Current Opinion in Rheumatology</i> , 2002, 14, 15-22.	2.0	70
23	Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study. <i>BMC Nephrology</i> , 2019, 20, 58.	0.8	64
24	Recurrences and Infections During Continuous Immunosuppressive Therapy After Beginning Dialysis in ANCA-Associated Vasculitis. <i>American Journal of Kidney Diseases</i> , 2007, 50, 36-46.	2.1	59
25	CD4+CD28 ^{hi} T cell expansion in granulomatosis with polyangiitis (Wegener's) is driven by latent cytomegalovirus infection and is associated with an increased risk of infection and mortality. <i>Arthritis and Rheumatism</i> , 2011, 63, 2127-2137.	6.7	56
26	Explaining fatigue in ANCA-associated vasculitis. <i>Rheumatology</i> , 2013, 52, 1680-1685.	0.9	50
27	Cardiovascular, thromboembolic and renal outcomes in IgA vasculitis (Henoch-Schönlein purpura): a retrospective cohort study using routinely collected primary care data. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 261-269.	0.5	50
28	Complications of long-term therapy for ANCA-associated systemic vasculitis. <i>Nature Reviews Nephrology</i> , 2012, 8, 523-532.	4.1	49
29	Intravenous Cyclophosphamide and Plasmapheresis in Dialysis-Dependent ANCA-Associated Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 219-224.	2.2	49
30	Skewed Fc Glycosylation Profiles of Anti-proteinase 3 Immunoglobulin G1 Autoantibodies from Granulomatosis with Polyangiitis Patients Show Low Levels of Bisection, Galactosylation, and Sialylation. <i>Journal of Proteome Research</i> , 2015, 14, 1657-1665.	1.8	49
31	Adverse effects of therapy for ANCA-associated vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 391-401.	1.4	46
32	Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse. <i>Arthritis Research and Therapy</i> , 2017, 19, 129.	1.6	42
33	Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. <i>Rheumatology</i> , 2020, 59, e24-e32.	0.9	42
34	Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Rheumatology</i> , 2014, 53, 953-956.	0.9	38
35	Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases. <i>Rheumatology</i> , 2019, 58, 889-896.	0.9	35
36	Avoidance of Harm From Treatment for ANCA-Associated Vasculitis. <i>Current Treatment Options in Rheumatology</i> , 2017, 3, 230-243.	0.6	30

#	ARTICLE	IF	CITATIONS
37	Subclinical Reactivation of Cytomegalovirus Drives CD4+CD28null T-Cell Expansion and Impaired Immune Response to Pneumococcal Vaccination in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Journal of Infectious Diseases</i> , 2019, 219, 234-244.	1.9	26
38	Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review. <i>Autoimmunity Reviews</i> , 2019, 18, 535-541.	2.5	26
39	Successful outcome of pregnancy in patients with anti-neutrophil cytoplasm antibody-associated small vessel vasculitis. <i>Kidney International</i> , 2015, 87, 807-811.	2.6	23
40	The European Vasculitis Society 2016 Meeting Report. <i>Kidney International Reports</i> , 2017, 2, 1018-1031.	0.4	21
41	The host cellular immune response to cytomegalovirus targets the endothelium and is associated with increased arterial stiffness in ANCA-associated vasculitis. <i>Arthritis Research and Therapy</i> , 2018, 20, 194.	1.6	20
42	Cardiovascular and Renal Morbidity in Takayasu Arteritis: A Population-Based Retrospective Cohort Study From the United Kingdom. <i>Arthritis and Rheumatology</i> , 2021, 73, 504-511.	2.9	20
43	Physical Fatigue, Fitness, and Muscle Function in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis Care and Research</i> , 2016, 68, 1332-1339.	1.5	19
44	Glucocorticoid induced adrenal insufficiency is common in steroid treated glomerular diseases - proposed strategy for screening and management. <i>BMC Nephrology</i> , 2019, 20, 154.	0.8	18
45	CD4+CD28 T-cell expansions in ANCA-associated vasculitis and association with arterial stiffness: baseline data from a randomised controlled trial. <i>Lancet</i> , 2015, 385, S30.	6.3	17
46	Association of Low B Cell Count and IgG Levels With Infection, and Poor Vaccine Response With All-Cause Mortality in an Immunosuppressed Vasculitis Population. <i>Arthritis Care and Research</i> , 2016, 68, 853-860.	1.5	17
47	Endothelial Nitric Oxide Synthase Single Nucleotide Polymorphism and Left Ventricular Function in Early Chronic Kidney Disease. <i>PLoS ONE</i> , 2015, 10, e0116160.	1.1	15
48	Treatment of fatigue with physical activity and behavioural change support in vasculitis: study protocol for an open-label randomised controlled feasibility study. <i>BMJ Open</i> , 2018, 8, e023769.	0.8	14
49	The complications of vasculitis and its treatment. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 125-136.	1.4	13
50	Predicting relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis: a Systematic review and meta-analysis. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab018.	0.3	13
51	Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 338.	0.7	12
52	Cardiovascular, muscular and perceptual contributions to physical fatigue in prevalent kidney transplant recipients. <i>Transplant International</i> , 2016, 29, 338-351.	0.8	12
53	The Longitudinal Course of Fatigue in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2020, 47, 572-579.	1.0	12
54	Hemodialysis Patients Make Long-Lived Antibodies against SARS-CoV-2 that May Be Associated with Reduced Reinfection. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2140-2142.	3.0	12

#	ARTICLE	IF	CITATIONS
55	ANCA-associated vasculitis: new options beyond steroids and cytotoxic drugs. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 689-703.	1.9	11
56	Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2015, 30 Suppl 1, i164-70.	0.4	10
57	Caveolin-1 single-nucleotide polymorphism and arterial stiffness in non-dialysis chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1140-1144.	0.4	10
58	Management of fatigue with physical activity and behavioural change support in vasculitis: a feasibility study. <i>Rheumatology</i> , 2021, 60, 4130-4140.	0.9	10
59	L42. Morbidity in patients with ANCA-associated vasculitis. <i>Presse Medicale</i> , 2013, 42, 612-616.	0.8	9
60	Podocytes and Proteinuria in ANCA-Associated Glomerulonephritis: A Case-Control Study. <i>Frontiers in Immunology</i> , 2019, 10, 1405.	2.2	9
61	ANCA-associated vasculitides—lessons from the adult literature. <i>Pediatric Nephrology</i> , 2010, 25, 1397-1407.	0.9	7
62	Latent Cytomegalovirus Infection and Previous Capsular Polysaccharide Vaccination Predict Poor Vaccine Responses in Older Adults, Independent of Chronic Kidney Disease. <i>Clinical Infectious Diseases</i> , 2021, 73, e880-e889.	2.9	6
63	Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis. <i>Journal of Rheumatology</i> , 2020, 47, 580-588.	1.0	5
64	Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines—Executive summary. <i>Rheumatology</i> , 2020, 59, 727-731.	0.9	5
65	Recent advances to achieve remission induction in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Current Opinion in Rheumatology</i> , 2010, 22, 37-42.	2.0	4
66	Humoral immunity to memory antigens and pathogens is maintained in patients with chronic kidney disease. <i>PLoS ONE</i> , 2018, 13, e0195730.	1.1	4
67	Decreased renal function is associated with incident dementia: An IMRD—THIN retrospective cohort study in the UK. <i>Alzheimer's and Dementia</i> , 2022, , .	0.4	4
68	ANCA-associated vasculitis: is there a role for neutrophil apoptosis in autoimmunity?. <i>Expert Review of Clinical Immunology</i> , 2006, 2, 237-244.	1.3	3
69	The Sound of Interconnectivity; The European Vasculitis Society 2022 Report. <i>Kidney International Reports</i> , 2022, 7, 1745-1757.	0.4	3
70	Small vessel vasculitides. <i>Medicine</i> , 2014, 42, 138-145.	0.2	2
71	Addressing the transition to a chronic condition: exploring independent adoption of self-management by patients with ANCA-associated vasculitis. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab075.	0.3	2
72	How does the outcome of research training fellowships funded via the NHS compare with that from competitively funded fellowships from the MRC and other charities: a cross-sectional retrospective survey of trainees undertaking research training in the West Midlands. <i>BMJ Open</i> , 2018, 8, e019630.	0.8	1

#	ARTICLE	IF	CITATIONS
73	Response to "IgA vasculitis in adults: few certainties and many uncertainties"™ by Hořevár et al. Annals of the Rheumatic Diseases, 2020, 79, e48-e48.	0.5	1
74	Psychological and self-management support for people with vasculitis or connective tissue diseases: UK health professionals™ perspectives. Rheumatology Advances in Practice, 2020, 4, rkaa016.	0.3	1
75	Response to: "Mycophenolate mofetil: a step forward in the induction treatment of ANCA-associated vasculitis? Comment on the article by Jones<i>et al</i>™</i> by Vandergheynst<i>et al</i>. Annals of the Rheumatic Diseases, 2020, 79, e101-e101.	0.5	0
76	Response to: "MYCYC, unravelling the long road ahead in ANCA-associated vasculitis"™ by Jain <i>et al</i>. Annals of the Rheumatic Diseases, 2020, 79, e58-e58.	0.5	0
77	B cell therapies in antineutrophil cytoplasmic antibody-associated vasculitis: why measure B cells and immunoglobulins?. Nephrology Dialysis Transplantation, 2020, , .	0.4	0
78	Reply. Arthritis and Rheumatology, 2021, 73, 1948-1950.	2.9	0
79	Reply. Arthritis and Rheumatology, 2021, 73, 2145-2146.	2.9	0
80	Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis. Rheumatology Advances in Practice, 2021, 5, rkab039.	0.3	0
81	Antineutrophil Cytoplasm Antibody-associated Vasculitis. , 2013, , 1481-1497.e4.		0
82	MO250: COVID-19 Associated Collapsing Variant of Focal Segmental Glomerulosclerosis: A Case Series of 7 Patients from a Single UK Centre. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0